AlphAIalphai — Financial news for AI agents
stocktwits.comAUG 202 min read$TRLV

MSOS Hits 2026 High: Which Cannabis Stock Could Light Up Portfolios Ahead Of DEA Hearing?

MSOS, an ETF focused on cannabis stocks, reached its highest level in 2026. Trulieve, its largest holding, began trading on the NYSE under TRLV. The DEA hearing in June could reschedule marijuana, boosting the sector. MSOS has a 103.7% NAV return over one year, outperforming key indices. AdvisorShares and Alliance Global highlight potential benefits from rescheduling, including improved earnings and capital access.

Original reporting
stocktwits.com
Published Aug 20, 2026, 5:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 4:40 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
MSOS Hits 2026 High: Which Cannabis Stock Could Light Up Portfolios Ahead Of DEA Hearing? — source image
Source · stocktwits.com
Decision brief

The 30-second read

$TRLVBullishLow
01

Why it matters

The uplisting and regulatory hearing are fresh catalysts that could drive short-term inflows into cannabis equities and ETFs.

02

Market read

Regulatory and listing news may boost cannabis sector sentiment and ETF performance.

03

What to watch

Potential resistance from state regulators or banking restrictions may limit upside.

Relevance 6/10Novelty 5/10Timing: upcoming Wednesday listing and DEA hearing later this month

Background

The article discusses the impact of a pending DEA hearing and a new NYSE listing for Trulieve on the cannabis sector and the MSOS ETF.

Company-level read

Ticker impact

$TRLVBullishMedium confidence
Context

Trulieve announced its shares will begin trading on the NYSE under the symbol TRLV on Wednesday.

Expected impact

initial trading may see a premium over OTC price

Evidence & confidence

Uplist is a primary disclosure that may materially affect liquidity and valuation.

Market effects

Sector

Regulatory progress could benefit the broader medical cannabis sector.

Regional

U.S. cannabis companies may see improved access to capital and banking services.

Global

International investors may increase exposure to U.S. cannabis via ETFs like MSOS.

Counterpoint

What could challenge this read

If the DEA hearing stalls or results in a less favorable outcome, the rally could reverse.

Key entities

  • ETF
    MSOS

    AdvisorShares Pure US Cannabis ETF

  • Company
    Trulieve Cannabis

    Largest holding of MSOS, moving to NYSE

Read at source← All news

Related articles

AUG 29
$TRLVMed

Trulieve Cannabis (TRLV) Is Up 6.5% After ESOP-Linked US$55.5 Million Share Issuance - Has The Bull Case Changed?

Trulieve Cannabis (TRLV) issued 10 million shares worth $55.5 million in an ESOP-related offering, causing a 6.5% stock price increase. The company also authorized a $50 million share buyback program. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside and others a more pessimistic outlook. Q2 2026 sales declined year over year, and net loss widened, keeping margin trends and capital deployment in focus.

simplywall.st3 min
AUG 10
$TRLVMedAI 8/10

Trulieve Cannabis Q2 Earnings Call Highlights

Trulieve Cannabis reported Q2 revenue of $271 million, including $222 million medical-only revenue. Adjusted EBITDA was $98 million (36% margin). Operating cash flow was $53 million and free cash flow $32 million, with $325 million cash and $289 million debt. The company authorized a $50 million share repurchase program in June. It expects Q3 medical-only revenue comparable to $222 million and raised capex to $95 million.

yahoo.com7 min
AUG 7
$TRLVMedAI 8/10

Trulieve Reports Second Quarter 2026 Results

Trulieve Cannabis Corp. (NYSE: TRLV) reported Q2 2026 revenue of $271 million and 60% gross margin, with 94% of revenue from retail sales. GAAP net loss attributable to common shareholders was $406 million, including a $407 million impact from Harvest deconsolidation. Adjusted net income was $20 million. Cash flow from operations was $109 million and free cash flow $74 million for the first half. The company also announced a share repurchase program.

prnewswire.com6 min
AUG 7
MedAI 8/10

Why is Trulieve Cannabis stock rallying today?

Trulieve Cannabis (TRLV) shares rose 5.6% premarket to $9.50 after it reported Q2 2026 results before the open. The quarter was the first full period under federal rescheduling of state-legal medical cannabis from Schedule I to III, removing 280E tax for qualifying operators, according to the DOJ and DEA. Analysts expected about $0.08 EPS on ~$272M revenue, and seven analysts rated TRLV Buy-equivalent with an average $18.71 target.

investing.com4 min
AUG 7
$TRLVMed

Trulieve Cannabis Corp. (TRLV): Completion of Acquisition or Disposition of Assets

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Trulieve Reports Second Quarter 2026 Results • Second quarter revenue of $271 million, with 60% gross margin • Cash flow from operations of $109 million and free cash flow of $74 million* in first half of 2026 • First U.S. Cannabis Company listed on New York Stock Ex

SEC EDGAR 8-K6 min
AUG 28
$BHPMedAI 8/10

Argentina, Chile Sign $20.7B Copper Project Pact

Argentina and Chile approved protocols to integrate three copper projects, unlocking $20.7B in investment. The projects, including Vicuña (Lundin Mining, BHP), NexoAndino, and Filo Sur, span the Andes. Chile's mining council highlights opportunities for suppliers and infrastructure. Argentina aims to boost copper production, with Morgan Stanley forecasting 1.2M tons annually by 2035, generating $26B in exports.

nuevoenfoqueurbano.com.ar2 min